Aurinia Pharmaceuticals Inc

16 de set. de 2026, 19:22 UTC

Aurinia Pharmaceuticals Inc shares are significantly higher after reporting a substantial increase in quarterly revenue and a rise in net income from LUPKYNIS sales.

15 de set. de 2026, 19:56 UTC

Aurinia Pharmaceuticals Inc. shares are trading lower amid broader market sentiment influenced by anticipated Federal Reserve rate hikes and rising Treasury yields.

14 de set. de 2026, 20:07 UTC

Aurinia Pharmaceuticals shares are higher amid market volatility and inflation concerns ahead of the Federal Reserve's interest rate decision.

10 de set. de 2026, 20:06 UTC

Aurinia Pharmaceuticals shares are lower today, influenced by broader market declines amid macroeconomic factors, including the European Central Bank's interest rate hike.

9 de set. de 2026, 20:41 UTC

Aurinia Pharmaceuticals Inc shares are higher in after-market trading, showing increased investor interest despite no specific company news, remaining above their 20-day moving average.

8 de set. de 2026, 23:36 UTC

Aurinia Pharmaceuticals Inc is trading lower in after-market hours, with no specific news identified to explain the movement. The stock remains within its one-month trading range.

1 de set. de 2026, 20:08 UTC

Aurinia Pharmaceuticals is declining amid broader market losses and rising inflation concerns, with no specific company news identified to explain the movement.

26 de ago. de 2026, 20:08 UTC

Aurinia Pharmaceuticals shares are lower amid broader Biotechnology sector weakness. A Form 4 filing revealed a $355,000 insider share sale by Chief Legal Officer Stephen P. Robertson.

25 de ago. de 2026, 19:36 UTC

Aurinia Pharmaceuticals Inc is trading higher amid a positive market environment, despite pulling back from earlier session highs. No specific news was identified.

24 de ago. de 2026, 22:01 UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, continuing a trend of declines observed over the past three sessions. No specific news was identified.

21 de ago. de 2026, 23:06 UTC

Aurinia Pharmaceuticals Inc. shares are higher in after-market hours, reflecting routine trading activity and maintaining a position above the 20-day moving average.

20 de ago. de 2026, 21:46 UTC

Aurinia Pharmaceuticals Inc shares are trading lower in after-market hours. No specific news was identified to explain the decline.

19 de ago. de 2026, 23:02 UTC

Aurinia Pharmaceuticals settled patent litigation with Teva, securing exclusivity for voclosporin until December 2036. Shares rose in after-hours trading following the announcement.

18 de ago. de 2026, 19:56 UTC

Aurinia Pharmaceuticals Inc is trading higher today, though no specific news has been identified. Rising Treasury yields may pose challenges for equities.

17 de ago. de 2026, 20:02 UTC

Aurinia Pharmaceuticals shares are lower amid broader market declines and rising crude oil prices, despite some social media chatter about potential buyout interest.

14 de ago. de 2026, 19:26 UTC

Aurinia Pharmaceuticals shares are higher today, rebounding after earlier volatility amid broader market concerns over disappointing U.S. retail sales figures.

13 de ago. de 2026, 19:56 UTC

Aurinia Pharmaceuticals shares are lower today, despite ongoing sales growth of Lupkynis and a recent acquisition of Kezar Life Sciences.

11 de ago. de 2026, 20:06 UTC

Aurinia Pharmaceuticals Inc shares are trading lower today, continuing a trend of three consecutive daily declines amid no specific news to explain the movement.

10 de ago. de 2026, 20:06 UTC

Aurinia Pharmaceuticals shares decline following multiple downgrades from research firms, despite Royal Bank of Canada raising its price target to $16.00.

7 de ago. de 2026, 19:16 UTC

Aurinia Pharmaceuticals shares are lower today, despite earlier gains. RBC Capital raised the price target to $16.00 from $15.00, maintaining a Sector Perform rating.

6 de ago. de 2026, 20:02 UTC

Aurinia Pharmaceuticals reported second-quarter EPS of $0.28, exceeding estimates. The stock is higher today amid strong financial results and reaffirmed revenue guidance for 2026.

4 de ago. de 2026, 19:46 UTC

Aurinia Pharmaceuticals Inc is trading higher amid a positive market environment and a decline in crude oil prices, which may benefit consumer spending.

3 de ago. de 2026, 22:01 UTC

Aurinia Pharmaceuticals shares are higher in after-market hours, despite being below the 20-day moving average and three prior lower daily closes.

1 de ago. de 2026, 00:01 UTC

Aurinia Pharmaceuticals Inc is trading lower in after-market hours, reflecting a significant decline in the overall market and ongoing weakness in performance metrics.

31 de jul. de 2026, 21:01 UTC

Aurinia Pharmaceuticals Inc is higher in after-market trading, rising notably from a flat start. The stock remains below its 20-day moving average.

30 de jul. de 2026, 20:31 UTC

Aurinia Pharmaceuticals Inc. shares rose in after-market trading, following a broader market trend as the S&P 500 also gained. No specific news was identified.

29 de jul. de 2026, 22:01 UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, showing notable weakness and trading below its 20-day moving average. No specific news was identified.

28 de jul. de 2026, 19:36 UTC

Aurinia Pharmaceuticals shares are lower, reflecting volatility amid broader market conditions. The stock is trading significantly below its 20-day moving average.

27 de jul. de 2026, 19:16 UTC

Aurinia Pharmaceuticals is trading higher, benefiting from lower oil prices and easing inflation concerns ahead of the Federal Reserve meeting later this week.

24 de jul. de 2026, 18:26 UTC

Aurinia Pharmaceuticals is trading higher, despite pulling back from earlier gains. Broader market volatility, influenced by declining oil prices, impacts sentiment.